prodigiosene + 4-hydroxytamoxifen

Prodigiosene + 4-hydroxytamoxifen is a research-stage conjugate molecule consisting of a synthetic prodigiosene—a tripyrrolic pigment analog with known immunosuppressive, antimicrobial, and anticancer properties—covalently linked to 4-hydroxytamoxifen (4-OHT), the active metabolite of tamoxifen and a selective estrogen receptor modulator (SERM). Developed in academic research, particularly by Alison Thompson's group at Dalhousie University, this conjugate is designed to selectively target estrogen receptor-positive breast cancer cells (such as the MCF-7 cell line) to overcome the lack of specificity of free prodigiosenes. The conjugate exhibits nanomolar-range in vitro activity against MCF-7 breast cancer cells, inducing apoptosis through mechanisms that include DNA cleavage, transmembrane anion transport, and estrogen receptor binding. It remains a preclinical research compound with no commercial developer or approved clinical indications.

Other names

4-hydroxytamoxifen-prodigiosene conjugateprodigiosene-4-hydroxytamoxifen conjugateprodigiosene4-hydroxytamoxifen conjugateprodigiosene 4-hydroxytamoxifen conjugateprodigiosene-tamoxifen conjugateprodigiosin-tamoxifen conjugate